Ivabradine, Heart Failure and Chronic Kidney Disease | Zendy

Luca Di Lullo | Zendy; Antonio Bellasi | Zendy; Domenico Russo | Zendy; Mario Cozzolino | Zendy; Claudio Ronco | Zendy; Alberto Santoboni | Zendy; G Barberá | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ivabradine, Heart Failure and Chronic Kidney Disease

Author(s) -

Luca Di Lullo,

Antonio Bellasi,

Domenico Russo,

Mario Cozzolino,

Claudio Ronco,

Alberto Santoboni,

G Barberá

Publication year - 2015

Publication title -

nephrology point of care

Language(s) - English

Resource type - Journals

ISSN - 2059-3007

DOI - 10.5301/poc.5000190

Subject(s) - heart failure , ivabradine , medicine , kidney disease , intensive care medicine , quality of life (healthcare) , clinical trial , incidence (geometry) , disease , cardiology , physical therapy , blood pressure , heart rate , physics , nursing , optics

The incidence and prevalence of congestive heart failure are actually increasing worldwide, especially in Western countries. In Europe and the United States, congestive heart failure represents a disabling clinical disease, accountable for increased hospitalization and health care costs. European guidelines have underlined the importance of pharmacological treatment to improve both patients’ outcomes and quality of life. The latest clinical trials to evaluate ivabradine’s efficacy have underlined its usefulness as a stand-alone medication and in combination with conventional congestive heart failure therapy, including in chronic kidney disease patients

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research